Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Registro completo
Provedor de dados:  BJID
País:  Brazil
Título:  Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach
Autores:  Benzaken,Adele Schwartz
Girade,Renato
Catapan,Elisa
Pereira,Gerson Fernando Mendes
Almeida,Elton Carlos de
Vivaldini,Simone
Fernandes,Neide
Razavi,Homie
Schmelzer,Jonathan
Ferraz,Maria Lucia
Ferreira,Paulo Roberto Abrão
Pessoa,Mario Guimarães
Martinelli,Ana
Souto,Francisco José Dutra
Walsh,Nick
Mendes-Correa,Maria Cassia
Data:  2019-06-01
Ano:  2019
Palavras-chave:  Hepatitis C
Hepatitis C elimination
Hepatitis C disease burden
Brazil
Resumo:  ABSTRACT Introduction and aim: Hepatitis C is a key challenge to public health in Brazil. The objective of this paper was to describe the Brazilian strategy for hepatitis C to meet the 2030 elimination goal proposed by World Health Organization (WHO). Methods: A mathematical modeling approach was used to estimate the current HCV-infected Brazilian population, and to evaluate the relative costs of two different scenarios to address HCV disease burden in Brazil: (1) if no further changes are made to the HCV treatment program in Brazil; (2) where the WHO targets for 2030 elimination are met through diagnosis and treatment efforts peaking before 2024. Results: An anti-HCV prevalence of 0.53% was calculated for the total population. It was estimated that the number of HCV-RNA+ individuals in Brazil in 2017 was 632,000 (0.31% of the population). Scale-up of treatment and diagnosis over time will be necessary in order to achieve WHO targets beginning in 2018. Direct costs (diagnostic, treatment and healthcare costs) are projected to increase significantly during the scale-up of treatment and diagnosis in the initial years of the intervention scenario, but then fall below the base case on an annual basis by 2025-2036, once HCV is eliminated, due to health sectors savings from the prevention of HCV liver-related morbidity and mortality. Conclusion: Achieving the WHO targets is technically feasible in Brazil with a scale-up of treatment and diagnosis over time, beginning in 2018. However, elimination of hepatitis C requires policy changes to substantially scale-up prevention, screening and treatment of HCV, together with public health advocacy to raise awareness among affected populations and healthcare providers.
Tipo:  Info:eu-repo/semantics/article
Idioma:  Inglês
Identificador:  http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702019000300182
Editor:  Brazilian Society of Infectious Diseases
Relação:  10.1016/j.bjid.2019.04.010
Formato:  text/html
Fonte:  Brazilian Journal of Infectious Diseases v.23 n.3 2019
Direitos:  info:eu-repo/semantics/openAccess
Fechar
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional